Pablo Proano, MD
Psychiatry · Seattle, WANPI 1639109036
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,329 of the $111,883 with a category attached, or 61.1%. 29 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 41.3% of the total. Reporting peaked in 2019 at $43,124 and has fallen 87.1% since, to $5,577 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,153 payments — averaging $97.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$46K
- Otsuka America Pharmaceutical, Inc.$35K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
- AbbVie$4K
- Neurocrine Biosciences, Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $14K from 23 others
What the payments were for
- Consulting fees$2,9403%
- Speaking & faculty fees$68,32961%
- Travel & lodging$8,7098%
- Food & beverage$31,79028%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 102 | $46,230 |
| Otsuka America Pharmaceutical, Inc. | 130 | $34,849 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 153 | $7,463 |
| AbbVie(2 entities) | 202 | $4,434 |
| Neurocrine Biosciences, Inc. | 86 | $2,675 |
| Takeda Pharmaceuticals U.S.A., Inc. | 88 | $2,248 |
| Sunovion Pharmaceuticals Inc. | 8 | $1,729 |
| Alkermes, Inc. | 47 | $1,691 |
| Axsome Therapeutics, Inc. | 30 | $1,544 |
| Johnson & Johnson | 37 | $1,458 |
| Supernus Pharmaceuticals, Inc. | 56 | $1,072 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $945 |
| Lundbeck LLC | 35 | $726 |
| Corium, LLC | 22 | $666 |
| Vanda Pharmaceuticals Inc. | 15 | $654 |
| E.r. Squibb & Sons, L.L.C. | 12 | $621 |
| Jazz Pharmaceuticals Inc. | 8 | $471 |
| Avanir Pharmaceuticals, Inc. | 22 | $464 |
| Idorsia Pharmaceuticals US Inc | 16 | $338 |
| Alfasigma USA, Inc. | 19 | $330 |
| Tris Pharma Inc | 10 | $295 |
| Ironshore Pharmaceuticals Inc. | 5 | $242 |
| Eisai Inc. | 12 | $204 |
| Shire North American Group Inc | 9 | $171 |
| Bausch Health US, LLC | 5 | $101 |
| Adlon Therapeutics L.p. | 5 | $93 |
| Noven Therapeutics, LLC | 4 | $83 |
| Merck | 4 | $69 |
| Biodelivery Sciences International, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$43,978
- REXULTI$32,889
- CAPLYTA$4,446
- LYBALVI$2,767
- LATUDA$1,069
- Auvelity$725
- INGREZZA$666
- SUNOSI$623
- SPRAVATO$614
- VRAYLAR$605
- Fanapt$373
- TRINTELLIX$340
- COBENFY$280
- Austedo XR$253
- ABILIFY MAINTENA$244
- Jornay PM 20mg capsules (Bottle of 100)$168
- ABILIFY ASIMTUFII$125
- UZEDY$125
- Dyanavel XR$125
- Quillivant$125
How this compares
$111,883 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 35 | $293,294 |
| AustedoDeutetrabenazine | 14 | $213,641 |
| RexultiBrexpiprazole | 48 | $85,203 |
| VraylarCariprazine Hcl | 51 | $84,757 |
| Invega SustennaPaliperidone Palmitate | 14 | $51,489 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $35,445 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $25,249 |
| CaplytaLumateperone Tosylate | 13 | $18,173 |
| TrintellixVortioxetine Hydrobromide | 11 | $16,022 |
| QuviviqDaridorexant Hcl | 12 | $5,864 |
| Bupropion XlBupropion Hcl | 178 | $3,997 |
| Buspirone Hcl | 150 | $3,457 |
| Doxepin Hcl | 104 | $3,143 |
| Quetiapine Fumarate | 97 | $3,076 |
| Atomoxetine Hcl | 35 | $2,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,675 | $293,29435 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $46,230 | $213,64114 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $34,849 | $85,20348 claims |
| AbbVieVraylar | $4,434 | $84,75751 claims |
| Johnson & JohnsonInvega Sustenna | $1,458 | $51,48914 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $464 | $35,44515 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,544 | $25,24921 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $7,463 | $18,17313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $2,248 | $16,02211 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $338 | $5,86412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 psychiatry providers in Washington.
Other psychiatry in Seattle
- Chester RobachinskiSeattle$1.1M
- Jesse McClellandSeattle$39K
- Lina FineSeattle$30K
- Jonathan BuchholzSeattle$7K
- Steven MitchellSeattle$7K
- Randall EspinozaSeattle$6K
- John KernSeattle$6K
- James BowenSeattle$4K
- Gerard ZanolliSeattle$3K
- Shahm MartiniSeattle$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.